tradmap

FENC FENNEC PHARMACEUTICALS INC.

$12.54 +1.70%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

FENNEC PHARMACEUTICALS INC. (FENC) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry. Shares last traded at $12.54, 4.5% below their 52-week high. Over the past year the stock is up 41.9%. Net profit margin is -5.5%, below the peer median of 5.3%. Revenue declined 6.1% year over year.

Market Cap
Shares Out
EPS (TTM)
$-0.27
P/E Ratio
P/S Ratio
P/B Ratio
Dividend / Share
Dividend Yield
52-Week High
$13.13
52-Week Low
$5.66
Volume
8,520
Avg Vol (3m)
12,189.714

Performance

1W
+6.45%
1M
+19.14%
3M
+36.90%
6M
+57.93%
YTD
+62.86%
1Y
+41.86%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
60.19
SMA (50)
$10.98
SMA (200)
$8.62
Price vs SMA50
+14.17%
Price vs SMA200
+45.44%
ATR (14)
$0.61

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$59M
Net Income
$-3M
Gross Margin
33.8%
Operating Margin
-1.9%
Net Margin
-5.5%
Return on Equity
-7.7%
Return on Assets
-4.3%
Current Ratio
5.85
Debt / Equity
0.46
Revenue Growth (YoY)
-6.1%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $0.06 2026-08-13
Q1 2026 $0.01 2026-05-14
FY 2025 $-0.34 2026-03-27
Q3 2025 $-0.18 2025-11-13
Q2 2026 $-0.16 2026-08-13
Q1 2026 $-0.04 2026-05-14

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

FENC vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.